Notizie AIOM – anno XV
FDA Approves Ribociclib for Frontline HR+/HER2- Breast Cancer
March 13, 2017 - The FDA has approved the CDK 4/6 inhibitor ribociclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer. The approval is ...Leggi tutto
FDA Places Partial Clinical Hold on Selinexor Trials
March 14, 2017 - The FDA has placed a partial clinical hold on trials of selinexor (KPT-330), which is being explored in several tumor types. Although the hold stops additional enrollment in the trials, patients who have achieved stable disease (SD) or better can continue ...Leggi tutto
Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity
Metastatic and recurrent cervical cancer is rarely a curable disease. Systemic chemotherapy is typically recommended for treatment based on clinical trials in the first-line or second-line setting. Rare patients who progress through 2 salvage regimens will have the performance ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore al seno è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...Leggi tutto